No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
2011-2012 seasonal flu vaccine |
- |
- |
- |
- |
2件: 3, 113 |
2 |
4-aminopyridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
2件: 3, 13 |
3 |
4-cholesten-3-one, oxime |
- |
- |
- |
- |
2件: 2, 3 |
4 |
4-cholesten-3-one,oxime |
- |
- |
- |
- |
1件: 3 |
5 |
Adipose derived mesenchymal stem cell |
- |
- |
- |
- |
1件: 3 |
6 |
Amifampridine |
Amifampridine |
D10228 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
3件: 3, 11, 12 |
7 |
Amifampridine phosphate |
Amifampridine |
D10228 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
3件: 3, 11, 12 |
8 |
Amifampridine phosphate 10 mg oral tablet |
Amifampridine |
D10228 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 3 |
9 |
Avxs-101 |
- |
- |
- |
- |
1件: 3 |
10 |
Avxs-101 (previously known as scaav9.cb.smn) |
- |
- |
- |
- |
1件: 3 |
11 |
Biocarn |
- |
- |
- |
- |
1件: 3 |
12 |
Branaplam |
Branaplam |
- |
- |
- |
1件: 3 |
13 |
Celecoxib |
Celecoxib |
D00567 |
1件: PTGS2 |
20件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
8件: 2, 3, 34, 46, 70, 89, 161, 271 |
14 |
Ck-2127107 |
Reldesemtiv |
D11363 |
1件: TNNC2 |
1件: Calcium signaling pathway |
2件: 2, 3 |
15 |
Ck-2127107 150 mg |
Reldesemtiv |
D11363 |
1件: TNNC2 |
1件: Calcium signaling pathway |
1件: 3 |
16 |
Ck-2127107 450 mg |
Reldesemtiv |
D11363 |
1件: TNNC2 |
1件: Calcium signaling pathway |
1件: 3 |
17 |
Human anti-promyostatin monoclonal antibody |
- |
- |
- |
- |
1件: 3 |
18 |
Hydroxyurea |
Hydroxyurea |
D00341 |
1件: RRM2 |
6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
8件: 3, 13, 19, 20, 65, 85, 86, 284 |
19 |
Isis 396443 |
- |
- |
- |
- |
1件: 3 |
20 |
Isis 396443 (biib058) |
- |
- |
- |
- |
1件: 3 |
21 |
Itraconazole |
Itraconazole |
D00350 |
- |
- |
4件: 3, 65, 227, 299 |
22 |
Leuprolide |
Leuprolide |
D00989, D08113 |
1件: GNRHR |
2件: GnRH signaling pathway, Neuroactive ligand-receptor interaction |
5件: 1, 2, 3, 51, 76 |
23 |
Levocarnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
3件: 3, 53, 97 |
24 |
Lmi070 |
- |
- |
- |
- |
1件: 3 |
25 |
Mestinon |
Pyridostigmine |
D00487 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
3件: 3, 6, 11 |
26 |
Midazolam |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
27 |
N.a. |
- |
- |
- |
- |
8件: 3, 6, 8, 13, 46, 97, 240, 256 |
28 |
Nerve growth factor |
Nerve growth factor |
- |
- |
- |
2件: 3, 90 |
29 |
Norditropin simplexx |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
4件: 3, 78, 193, 195 |
30 |
Norditropin simplexx 15 mg/1.5 ml |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 3 |
31 |
Nusinersen |
Nusinersen |
D10881 |
1件: SMN2 |
1件: RNA transport |
1件: 3 |
32 |
Olesoxime |
- |
- |
- |
- |
2件: 2, 3 |
33 |
Onasemnogene abeparvovec |
- |
- |
- |
- |
1件: 3 |
34 |
Onasemnogene abeparvovec-xioi |
- |
- |
- |
- |
1件: 3 |
35 |
Orfiril saft |
- |
- |
- |
- |
1件: 3 |
36 |
Paracetamol |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
5件: 3, 6, 13, 35, 46 |
37 |
Paracetamol 120mg/5ml oral suspension |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 3 |
38 |
Phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
10件: 2, 3, 6, 8, 93, 94, 244, 251, 297, 299 |
39 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
40 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
41 |
Pyridostigmine |
Pyridostigmine |
D00487 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
4件: 3, 6, 11, 256 |
42 |
Pyridostigmine bromide |
Pyridostigmine |
D00487 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
3件: 3, 6, 256 |
43 |
Riluzole |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
7件: 2, 3, 5, 8, 13, 17, 206 |
44 |
Risdiplam |
Risdiplam |
D11406 |
1件: SMN2 |
1件: RNA transport |
1件: 3 |
45 |
Ro6885247/f03 |
- |
- |
- |
- |
1件: 3 |
46 |
Ro7034067 |
- |
- |
- |
- |
1件: 3 |
47 |
Ro7034067 / f12 |
- |
- |
- |
- |
1件: 3 |
48 |
Ro7034067 / f13 |
- |
- |
- |
- |
1件: 3 |
49 |
Ro7034067/f06 with solvent (ro7034067/f08) |
- |
- |
- |
- |
1件: 3 |
50 |
Ro7034067/f07 with solvent (ro7034067/f09) |
- |
- |
- |
- |
1件: 3 |
51 |
Ro7034067/f12 |
- |
- |
- |
- |
1件: 3 |
52 |
Ro7034067/f13 |
- |
- |
- |
- |
1件: 3 |
53 |
Ro7090919 |
- |
- |
- |
- |
1件: 3 |
54 |
Rvg 03820 |
- |
- |
- |
- |
1件: 3 |
55 |
Salbutamol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 3, 11, 49, 85, 86, 228, 256, 299 |
56 |
Sesame oil |
Sesame oil |
D03314 |
- |
- |
1件: 3 |
57 |
Sesame oil, refined |
Sesame oil |
D03314 |
- |
- |
1件: 3 |
58 |
Smart |
- |
- |
- |
- |
1件: 3 |
59 |
Sodium phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
4件: 2, 3, 8, 251 |
60 |
Sodium phenylbutyrate (napb) |
Phenylbutyric acid |
D05868 |
- |
- |
1件: 3 |
61 |
Somatropin |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
15件: 2, 3, 19, 46, 74, 75, 78, 96, 113, 193, 195, 265, 274, 276, 299 |
62 |
Spinraza |
Nusinersen |
D10881 |
1件: SMN2 |
1件: RNA transport |
1件: 3 |
63 |
Srk-015 |
- |
- |
- |
- |
1件: 3 |
64 |
Survival of motor neuron 2 (smn2) splicing modulator antisense oligonucleotide |
- |
- |
- |
- |
1件: 3 |
65 |
Testosterone |
Testosterone |
D00075, D00957, D00958, D00959, D06085, D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
7件: 1, 2, 3, 13, 78, 113, 265 |
66 |
Tro19622 |
Tro19622 |
- |
- |
- |
3件: 2, 3, 13 |
67 |
Valproate |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
6件: 2, 3, 90, 102, 233, 256 |
68 |
Valproate sodium |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 3 |
69 |
Valproate, levocarnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
1件: 3 |
70 |
Valproic acid |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
10件: 3, 5, 26, 34, 65, 89, 90, 222, 256, 331 |
71 |
Valproic acid (vpa) |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 3 |
72 |
Valproic acid and levocarnitine |
Levocarnitine, Valproic acid |
D00399, D02030, D02176, D04713 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 3 |
73 |
Volmax*30cpr 4mg r.p. |
- |
- |
- |
- |
1件: 3 |